RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
46 hedge funds and large institutions have $14.5M invested in RVL Pharmaceuticals plc Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 22 reducing their positions, and 19 closing their positions.
16% less funds holding
Funds holding: 55 → 46 (-9)
43% less capital invested
Capital invested by funds: $25.6M → $14.5M (-$11.1M)
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
73% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rovida Advisors
Fort Lauderdale,
Florida
|
+$919K |
| 2 |
Millennium Management
New York
|
+$490K |
| 3 |
E
Ergoteles
New York
|
+$175K |
| 4 |
HF
HRT Financial
New York
|
+$110K |
| 5 |
HW
Hancock Whitney
Gulfport,
Mississippi
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.52M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.69M |
| 3 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$1.11M |
| 4 |
Morgan Stanley
New York
|
-$802K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$703K |
RVLP Hedge Fund Activity: Q2 2021 in Review
46 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q2 2021, worth a combined $14.5M — down 43% from $25.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of RVLP and 10 opened new positions — a net loss of 9 holders — while 22 trimmed existing stakes and 6 added.
The largest buyer was Rovida Advisors, opening a new position worth an estimated $919K. The largest seller was BlackRock, cutting an estimated $3.52M.
- 46 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q2 2021, down from 55 in Q1 2021.
- Funds reported $14.5M of RVL Pharmaceuticals plc Ordinary Shares stock for Q2 2021, down 43% quarter-over-quarter.
- 10 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q2 2021 and 19 closed out, a net change of -9 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q2 2021 was Rovida Advisors, an estimated $919K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q2 2021 was BlackRock, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2021.